Next generation sequencing and its application in deciphering head and neck cancer.
Head and neck squamous cell carcinoma (HNSCC) are a group of heterogeneous tumours mainly attributable to tobacco use, alcohol consumption and infection with human papillomavirus. Based on the stage of cancer at the time of diagnosis, patients are managed by surgery, radiotherapy, chemotherapy or a combination of these. Early diagnosis usually improves patient prognosis. Since their first commercial application in 2005, next generation sequencing (NGS) platforms are rapidly changing the face of basic science laboratories; however prior to progressing to clinical applications, clinicians should carefully examine currently available data and guidelines for technical and ethical matters concerning NGS. In this review, we compare various commercially available NGS platforms, with special consideration given to their clinical application in the management of HNSCC.
The University of Queensland, UQ Centre for Clinical Research, Herston, Qld 4029, Australia; The University of Queensland, School of Dentistry, Brisbane, Qld 4000, Australia.
Maryam
M
Jessri
The University of Queensland, UQ Centre for Clinical Research, Herston, Qld 4029, Australia; The University of Queensland, School of Dentistry, Brisbane, Qld 4000, Australia. Electronic address: c.farah@uq.edu.au.
Camile S
CS
Farah
D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000628:therapy; D006801:Humans; D017421:Sequence Analysis / Q000379:methods*
Head and neck cancer; Next generation sequencing; Oral cancer; Personalized cancer therapy; RNA-seq